Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 7Leukemia, Myeloid, Acute 6Carcinoma, Hepatocellular 6Neoplasm Metastasis 5Colorectal Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Rectal Neoplasms 4Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Hematologic Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Acute Kidney Injury 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1

Interventions

Trastuzumab 1Oxaliplatin 1Fluorouracil 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × HER2-positive Gastric Cancer × Clear all
NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡